Interest in HIV vaccines among injection drug users in Baltimore, Maryland.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Interest in HIV vaccines among injection drug users in Baltimore, Maryland.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S265-8. Unique Identifier : AIDSLINE MED/95169496
Vlahov D; Astemborski J; Solomon L; Galai N; Basarab L; Nelson KE; Department of Epidemiology, Johns Hopkins School of Hygiene and; Public Health, Baltimore, Maryland 21205.

Abstract: To gauge interest about participation in human immunodeficiency virus type 1 (HIV vaccines, we interviewed 375 HIV-seronegative injecting drug users who are participants in an ongoing longitudinal study of HIV infection. Nearly all (93%) responded that they thought it likely that an HIV vaccine would become available, and 85% expressed interest in participating in a study of vaccine effectiveness. However, levels of interest decreased to 47% when respondents were informed that the vaccine might result in a positive HIV test and to 27% when offered to be in a study where the vaccine might contain a piece of the virus. Factors that increased interest in trial participation included assurances of confidentiality, being fully informed about the protocol and remuneration. Most respondents (78%) felt that injecting drug users would maintain other risk reduction activities (e.g., condom use) if they participated in a vaccine study. These data suggest a high level of interest for participation in HIV vaccine trials, but that more education about vaccines and the risks involved is needed. Ongoing communication with the community and responsiveness to community concerns is crucial to achieve a successful vaccine study.

Keywords: Adult AIDS Vaccines/*PHARMACOLOGY Baltimore Clinical Trials/METHODS/PSYCHOLOGY Female Human HIV Infections/PREVENTION & CONTROL/PSYCHOLOGY HIV Seronegativity *HIV-1 Longitudinal Studies Male Patient Education *Patient Selection Questionnaires *Substance Abuse, Intravenous/PSYCHOLOGY Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
950630
M9561120

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .